Absorb Bioresorbable Vascular Scaffold A Little Too Late

[1] Uptake of Drug-Eluting Bioresorbable Vascular Scaffolds in Clinical Practice An NCDR Registry to Practice Project [J]. JAMA CARDIOLOGY, 2019, 4 (06) : 564 - 568

[2] Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (20) : 1905 - 1915

[3] Erlinge D, 2024, LANCET, V404, P1750, DOI 10.1016/S0140-6736(24)02227-X

[4] Drug-coated balloon angioplasty with rescue stenting versus intended stenting for the treatment of patients with de novo coronary artery lesions (REC-CAGEFREE I) : an open-label, randomised, non-inferioritytrial [J]. LANCET, 2024, 404 (10457) : 1040 - 1050

[5] Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stent Implantation in Patients With Coronary Stent Restenosis [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (21) : 2664 - 2678

[6] Incidence and Imaging Outcomes of Acute Scaffold Disruption and Late Structural Discontinuity After Implantation of the Absorb Everolimus-Eluting Fully Bioresorbable Vascular Scaffold Optical Coherence Tomography Assessment in the ABSORB Cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) [J]. JACC-CARDIOVASCULAR INTERVENTIONS, 2014, 7 (12) : 1400 - 1411

[7] Time-Varying Outcomes With the Absorb Bioresorbable Vascular Scaffold During 5-Year Follow-up A Systematic Meta-analysis and Individual Patient Data Pooled Study [J]. JAMA CARDIOLOGY, 2019, 4 (12) : 1261 - 1269

[8] Paclitaxel-Coated Balloon vs Uncoated Balloon for Coronary In-Stent Restenosis [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024, 331 (12): : 1015 - 1024

[1] Uptake of Drug-Eluting Bioresorbable Vascular Scaffolds in Clinical Practice An NCDR Registry to Practice Project [J]. JAMA CARDIOLOGY, 2019, 4 (06) : 564 - 568

[2] Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (20) : 1905 - 1915

[3] Erlinge D, 2024, LANCET, V404, P1750, DOI 10.1016/S0140-6736(24)02227-X

[4] Drug-coated balloon angioplasty with rescue stenting versus intended stenting for the treatment of patients with de novo coronary artery lesions (REC-CAGEFREE I) : an open-label, randomised, non-inferioritytrial [J]. LANCET, 2024, 404 (10457) : 1040 - 1050

[5] Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stent Implantation in Patients With Coronary Stent Restenosis [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (21) : 2664 - 2678

[6] Incidence and Imaging Outcomes of Acute Scaffold Disruption and Late Structural Discontinuity After Implantation of the Absorb Everolimus-Eluting Fully Bioresorbable Vascular Scaffold Optical Coherence Tomography Assessment in the ABSORB Cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) [J]. JACC-CARDIOVASCULAR INTERVENTIONS, 2014, 7 (12) : 1400 - 1411

[7] Time-Varying Outcomes With the Absorb Bioresorbable Vascular Scaffold During 5-Year Follow-up A Systematic Meta-analysis and Individual Patient Data Pooled Study [J]. JAMA CARDIOLOGY, 2019, 4 (12) : 1261 - 1269

[8] Paclitaxel-Coated Balloon vs Uncoated Balloon for Coronary In-Stent Restenosis [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024, 331 (12): : 1015 - 1024